Vident Investment Advisory, LLC Bristol Myers Squibb CO Transaction History

Vident Investment Advisory, LLC

$0
Q3 2023

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$63.71 - $70.74 $5.15 Million - $5.72 Million	-80,803 Reduced 58.07%	58,348 $3.73 Million
Q1 2023 May 15, 2023	BUY	$65.71 - $74.53 $3.21 Million - $3.64 Million	48,888 Added 54.16%	139,151 $9.64 Million
Q4 2022 Feb 14, 2023	BUY	$68.48 - $81.09 $1.17 Million - $1.39 Million	17,089 Added 23.35%	90,263 $6.49 Million
Q3 2022 Nov 14, 2022	SELL	$0.13 - $76.84 $1,607 - $950,357	-12,368 Reduced 14.46%	73,174 $4.47 Million
Q2 2022 Aug 15, 2022	SELL	$72.62 - $79.98 $585,752 - $645,118	-8,066 Reduced 8.62%	85,542 $6.59 Million
Q1 2022 May 16, 2022	BUY	$61.48 - $73.72 $235,529 - $282,421	3,831 Added 4.27%	93,608 $6.84 Million
Q4 2021 Feb 14, 2022	SELL	$53.63 - $62.52 $248,467 - $289,655	-4,633 Reduced 4.91%	89,777 $5.6 Million
Q3 2021 Nov 12, 2021	BUY	$59.17 - $69.31 $1.35 Million - $1.59 Million	22,887 Added 32.0%	94,410 $5.59 Million
Q2 2021 Aug 13, 2021	BUY	$61.91 - $67.42 $193,283 - $210,485	3,122 Added 4.56%	71,523 $4.78 Million
Q1 2021 May 14, 2021	BUY	$59.34 - $66.74 $394,611 - $443,820	6,650 Added 10.77%	68,401 $4.32 Million
Q4 2020 Feb 08, 2021	BUY	$57.74 - $65.43 $413,360 - $468,413	7,159 Added 13.11%	61,751 $3.83 Million
Q3 2020 Nov 12, 2020	SELL	$57.43 - $63.64 $1.89 Million - $2.09 Million	-32,858 Reduced 37.57%	54,592 $3.29 Million
Q2 2020 Jul 28, 2020	SELL	$54.82 - $64.09 $1.95 Million - $2.28 Million	-35,510 Reduced 28.88%	87,450 $5.14 Million
Q2 2020 Jul 17, 2020	BUY	$54.82 - $64.09 $1.83 Million - $2.14 Million	33,395 Added 37.29%	122,960 $7.23 Million
Q1 2020 May 12, 2020	SELL	$46.4 - $67.43 $524,134 - $761,689	-11,296 Reduced 11.2%	89,565 $4.99 Million
Q4 2019 Feb 11, 2020	BUY	$49.21 - $64.19 $2.6 Million - $3.39 Million	52,811 Added 109.91%	100,861 $6.47 Million
Q3 2019 Nov 13, 2019	SELL	$42.77 - $50.71 $92,896 - $110,142	-2,172 Reduced 4.32%	48,050 $2.44 Million
Q2 2019 Aug 12, 2019	SELL	$44.62 - $49.34 $43,102 - $47,662	-966 Reduced 1.89%	50,222 $2.28 Million
Q1 2019 May 08, 2019	SELL	$45.12 - $53.8 $473,895 - $565,061	-10,503 Reduced 17.03%	51,188 $2.44 Million
Q4 2018 Feb 14, 2019	SELL	$48.76 - $63.23 $398,905 - $517,284	-8,181 Reduced 11.71%	61,691 $3.21 Million
Q3 2018 Nov 14, 2018	SELL	$55.19 - $62.25 $135,712 - $153,072	-2,459 Reduced 3.4%	69,872 $4.34 Million
Q2 2018 Aug 14, 2018	BUY	$50.53 - $62.98 $968,003 - $1.21 Million	19,157 Added 36.03%	72,331 $4 Million
Q1 2018 May 14, 2018	BUY	$59.92 - $68.98 $370,305 - $426,296	6,180 Added 13.15%	53,174 $2.86 Million
Q4 2017 Feb 15, 2018	SELL	$59.94 - $65.35 $148,950 - $162,394	-2,485 Reduced 5.02%	46,994 $2.88 Million
Q3 2017 Nov 14, 2017	BUY	$55.23 - $63.74 $2.73 Million - $3.15 Million	49,479	49,479 $3.15 Million

Others Institutions Holding BMY

# of Institutions

2,428

Shares Held

1.5B

Call Options Held

29.7M

Put Options Held

32.2M

Vanguard Group Inc Valley Forge, PA

187M
Shares

$9.92 Billion
0.15% of portfolio
Black Rock Inc. New York, NY

159M
Shares

$8.44 Billion
0.15% of portfolio
State Street Corp Boston, MA

91.4M
Shares

$4.86 Billion
0.17% of portfolio
Jpmorgan Chase & CO New York, NY

74.6M
Shares

$3.97 Billion
0.27% of portfolio
Charles Schwab Investment Management Inc San Francisco, CA

59.1M
Shares

$3.14 Billion
0.47% of portfolio

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $113B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vident Investment Advisory, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Vident Investment Advisory, LLC with notifications on news.

Account